Navigation Links
Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
Date:12/5/2007

LOUISVILLE, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that President and Chief Executive Officer Kenneth J. Collins will participate on the New and Powerful Anti-infectives panel at the RBC Capital Markets 2007 Healthcare Conference. The panel discussion will take place at 11:00 am ET on Thursday, December 13, 2007 at the Westin Times Square in New York City.

A live audio webcast of the panel discussion will be available on the investor relations section of the company's website at http://www.Replidyne.com. The webcast will be archived and available on Replidyne's website after the event for a period of 30 days.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its in-house discovery research.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
2. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
3. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
4. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
5. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
11. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec. 5, 2016  Pennsylvania Physician General Dr. ... Alcohol Programs Gary Tennis today filled prescriptions ... Minnich,s Pharmacy in York to ... by Dr. Levine as a prescription to acquire naloxone ... "It,s important to remember that any Pennsylvanian can walk ...
(Date:12/5/2016)... Research and Markets has announced the ... Application (Biomedical & Biochemical Research, Disease Diagnostics), End User (Academic & ... report to their offering. ... , , The western ... from USD 574.8 Million in 2016, growing at a CAGR of ...
(Date:12/5/2016)... CALEDONIA, Mich. , Dec. 5, 2016  Sharn ... a preferred anesthesia sales and distribution partner for Salter ... Dealer of the Year in recognition of outstanding sales ... of devices for respiratory and anesthesia care, including the ... company is also the master distributor of the Parker ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins ... growing brains of young athletes. Over the course of three years, researchers will study ... mouth guards. The mouth guards, equipped with special sensors, will track the location and ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... Isles Beach, Fla (PRWEB) , ... December 05, ... ... E. Herman as Keynote speaker for the 21st Annual International Congress on Hematologic ... making the announcement, PER® president, Phil Talamo said, “We are honored to have ...
(Date:12/5/2016)... Missouri (PRWEB) , ... December 05, 2016 , ... ... ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has always ... treatment accessible to as many people as possible. In that spirit, Castlewood ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
Breaking Medicine News(10 mins):